Fig. 2: Anti-human-TIGIT (anti-hu-TIGIT) agonistic mAb (αTIGIT) ameliorates EAE hu-TIGIT knock-in (KI) mice. | Communications Biology

Fig. 2: Anti-human-TIGIT (anti-hu-TIGIT) agonistic mAb (αTIGIT) ameliorates EAE hu-TIGIT knock-in (KI) mice.

From: Anti-human-TIGIT agonistic antibody ameliorates autoimmune diseases by inhibiting Tfh and Tph cells and enhancing Treg cells

Fig. 2: Anti-human-TIGIT (anti-hu-TIGIT) agonistic mAb (αTIGIT) ameliorates EAE hu-TIGIT knock-in (KI) mice.The alternative text for this image may have been generated using AI.

a The sorted Tfh cells were labelled with CellTrace violet (CTV) and activated with anti-CD3 and anti-CD28 Abs with plate-bound αTIGIT (or the appropriate isotype control) for 4 days. CTV dilution was analysed by flow cytometry. The suppression rate was calculated as follows: (1 − (proliferation rate of mAb)/(proliferation rate of isotype)) × 100) (mean + SEM) is shown (n = 2). Horizontal lines represent the mean of each group. b The strategy for generating hu-TIGIT KI mice is shown. c EAE immunisation and αTIGIT treatment protocols of 12-week-old male hu-TIGIT KI mice are shown. d EAE mice were divided into treated (n = 6, red) and nontreated (n = 6, black) groups, and the mean clinical score + or – SEM is shown. P values were determined by a two-tailed Student’s t test. *P < 0.05.

Back to article page